Compare iShares MBS ETF (MBB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares MBS ETF trades at $89.99 (market cap $35.76B), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: iShares MBS ETF is far larger — about 4.9× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 97 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MBB | SYRE | |
|---|---|---|
Market Cap | $35.76B | $7.35B |
Volume | 19,694,940 | 1,624,631 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $108.92 |
52-Week Low | $89.09 | $22.18 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.97 with minimal daily movement (+0.16%). The technical outlook is bearish with moving averages and oscillators signaling caution, though the stock shows strong institutional interest despite recent short interest growth. Recent news highlights Norway's sovereign wealth fund rotating into mortgage-backed securities, providing sector validation.
The ETF faces headwinds from rising intermediate-term rates and convexity risk, limiting upside potential. While dividend payments provide income, the bearish technical setup and interest rate sensitivity suggest cautious positioning. Institutional accumulation contrasts with growing short interest, creating mixed signals for investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
